PROCEPT BioRobotics Has Completed The First Commercial Aquablation Therapy Procedures In Japan, Carried Out At Two Medical Institutions, In Association With The 100-Patient Post-market Surveillance Study
Portfolio Pulse from Benzinga Newsdesk
PROCEPT BioRobotics has successfully completed the first commercial Aquablation therapy procedures in Japan at two medical institutions. This is in association with the 100-patient post-market surveillance study.
August 22, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PROCEPT BioRobotics' successful completion of the first commercial Aquablation therapy procedures in Japan could potentially boost its market presence and revenue in the region.
The successful completion of the first commercial Aquablation therapy procedures in Japan by PROCEPT BioRobotics is a significant milestone. This could potentially increase the company's market presence and revenue in Japan, a major healthcare market. Therefore, this news is likely to have a positive impact on PRCT's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100